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Cilnidipine, an L-/N-type calcium channel blocker, dilates the
efferent glomerular arterioles in an experimental model and
shows a renoprotective effect, but its clinical benefits and
safety have not yet been assessed in type II diabetics with
albuminuria. The objective of this trial was to evaluate the
effect of reducing albuminuria in type II diabetic patients
with a combination therapy consisting of valsartan plus
cilnidipine versus monotherapy with valsartan. An
open-label, randomized controlled trial was conducted from
April 2002 to October 2003 in 87 Japanese patients aged
31–90 years with type II diabetes showing albuminuria
(urinary albumin/creatinine ratio: 10–300 mg/g). The patients
were randomized to receive either valsartan (n¼ 41) or
valsartan plus cilnidipine (n¼ 46) once daily for 1 year. The
primary end point was the percent change in the albumin/
creatinine ratio. The secondary end points were the
progression/regression of albuminuria, blood pressure (BP),
renal function, and safety. After 1 year, the albumin/
creatinine ratio was found to have decreased more markedly
in the valsartan plus cilnidipine group than in the valsartan
group (reduction rate 44711% (s.e.) versus 977% (s.e.);
P¼ 0.014 by analysis of covariance). Although a significant
reduction was observed in the systolic and diastolic BP of
both groups from baseline to 1 year (Po0.0001, respectively),
there was no significant difference in the change in the BP
between the two groups (systolic BP, P¼ 0.066; diastolic BP,
P¼ 0.391). There were also no significant differences in the
side effects between the two groups. Cilnidipine was thus
found to show an additive effect with valsartan and thereby
caused a reduction in albuminuria in type II diabetics.
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For the treatment of hypertension in patients with diabetic
nephropathy, angiotensin II receptor blockers (ARBs) are
considered to be first-line drugs.1–4 For example, valsartan
has been shown to reduce microalbuminuria in patients with
type II diabetes mellitus and the reduction rate of micro-
albuminuria in the valsartan group was 44% in the MARVAL
trial.2 However, it is unclear as to whether the renoprotective
effect of valsartan alone is sufficient. As a result, to achieve a
clinically satisfactory decrease of microalbuminuria, it seems
likely that a second-line drug should be added to ARB
therapy.5
In patients with diabetic nephropathy, combination
therapy should be considered when the reduction of
microalbuminuria is incomplete with ARB monotherapy.
For example, diuretics and non-dihydropyridine calcium
channel blockers (CCBs) are recommended as second-line
drugs when the response to ARB monotherapy is inade-
quate.6 However, diuretics have metabolic side effects and
non-dihydropyridine CCBs have also shown a negative
inotropic effect. Dihydropyridine CCBs are used mainly in
Japan and amlodipine is used in more than 60% of all
patients taking dihydropyridine CCBs, but it remains unclear
whether this drug has a renoprotective effect or not.2
Furthermore, amlodipine has been shown to cause more
cardiovascular events and an incomplete efficacy in a
previous clinical trial.7
Among the available dihydropyridine CCBs, a novel L-/N-
type channel blocker, cilnidipine, has been demonstrated to
reduce proteinuria in hypertensive patients as effectively as
angiotensin-converting enzyme (ACE) inhibitor therapy.8
Cilnidipine has been shown to dilate efferent glomerular
arterioles as well as afferent ones in rats, and its renoprotec-
tive effect was stronger than its antihypertensive effect.9 The
reduction of proteinuria is explained by the fact that
cilnidipine blocks both N-type and L-type calcium channels,
thereby dilating the efferent glomerular arterioles and thus
reducing the glomerular pressure because N-type calcium
channels exist in both afferent and efferent arterioles. ARBs
act via a different mechanism through the rennin–angiotensin
system to reduce the glomerular pressure, so combination
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therapy with an ARB and cilnidipine may reduce the
glomerular pressure more markedly in an additive manner
when ARB monotherapy has an inadequate renoprotective
effect. However, there have so far been no clinical investiga-
tions into the effect of cilnidipine on albuminuria in patients
with type II diabetics who are on ARB therapy.
Therefore, we conducted a randomized prospective
clinical trial in 87 patients with type II diabetes showing
normo- and microalbuminuria to compare the renoprotec-
tive effect of valsartan monotherapy and combination
therapy using valsartan plus cilnidipine.
RESULTS
Study population
Of the 861 type II diabetic patients who were screened, 743
patients who showed overt proteinuria in the urinalysis
findings were excluded. Among the 118 patients whose
median urinary albumin–creatinine ratio (ACR) ranged from
10 to 300 mg/g during the 8-week period before entry, 24
patients were excluded since they did not give their consent
and seven patients were excluded for other reasons. The
remaining 87 patients with normoalbuminuria (urinary
ACR: 10–30 mg/g) or microalbuminuria (urinary ACR:
30–300 mg/g) were randomized into a treatment with
valsartan group (n¼ 41) or a valsartan plus cilnidipine
group (n¼ 46) (Figure 1). The baseline characteristics of the
patients in both groups are shown in Table 1. There were no
significant differences between the two groups. Amlodipine
was added to only one patient from the valsartan group. The
concomitant agents were used in seven patients (b-blocker
six and a-blocker one) in the monotherapy group and in
three patients (b-blocker three) in the combined therapy
group, respectively. After starting this trial, 12 patients
withdrew from each group. The main reasons for withdrawal
were discontinuation (nine patients from each group),
moving to another area (monotherapy: three, combined
therapy: two), and a protocol violation (one patient from the
combined therapy).
Primary outcome measure
The decrease in the ACR from baseline to 1 year was greater
in the combined therapy group than in the monotherapy
group (reduction rate 44711% (s.e.) versus 977% (s.e.);
P¼ 0.014 by analysis of covariance) (Figure 2).
Secondary outcome measures
The frequency of patients that improved from microalbumin-
uria to normoalbuminuria in the combined therapy group
tended to be higher than that in the monotherapy group
(37.9 versus 17.2%), although the difference was not
significant (P¼ 0.14). The frequency of patients progressing
from normoalbuminuria to microalbuminuria in the com-
bined therapy group tended to be lower than that in the
monotherapy group (5.9 versus 25%), although the differ-
ence was not significant (P¼ 0.28). One patient progressed to
overt proteinuria in the valsartan monotherapy group
(Table 2). Although a significant reduction in the systolic
and diastolic blood pressure (BP) was seen in both groups
from baseline to 1 year (Po0.0001, respectively), there was
no significant difference in the change of BP between the two
groups (systolic BP, P¼ 0.066; diastolic BP, P¼ 0.391)
(Table 3). There was no statistical correlation between the
861 patients screened
118 - or  for protein
734 excluded for
+ for protein
31 excluded
24 no consent
7 other reasons
87 randomly allocated
41 valsartan 46 valsartan plus cilnidipine
12 lost in follow-up
9 discontinuation
3 moved away
12 lost in follow-up
9 discontinuation
2 moved away
41 could be analyzed 39 could be analyzed
1 protocol invalidation
Figure 1 | Flow of participants through the trial.
Table 1 | Baseline characteristics
Variable
Valsartan
(n=41)
Valsartan+
cilnidipine
(n=46) P-value
Demographic
Age (years) 66712 67711 NS
Sex (male/female) 22/19 23/23 NS
Body mass index (kg/m2) 2474 2373 NS
Renal function
Serum creatinine (mg/dl) 0.870.3 0.770.2 NS
Calculated glomerular filtration
rate (ml/min/1.73 m2)
85734 85726 NS
Urinary albumin/creatinine
ratio (mg/g), geometric mean (IQR)
48 (27–96) 36 (17–62) NS
Arterial blood pressure
Systolic (mm Hg) 140714 135712 NS
Diastolic (mm Hg) 7779 7679 NS
Biochemistry tests
Serum potassium (mEq/l) 4.370.3 4.470.4 NS
Serum cholesterol (mg/dl) 207743 202733 NS
Serum triglycerides (mg/dl) 143782 116751 NS
Serum high-density lipoprotein (mg/dl) 52717 56721 NS
Uric acid (mg/dl) 5.371.7 4.771.1 NS
Glycosylated hemoglobin (%) 7.671.4 7.771.6 NS
Results are expressed as the mean7s.d. or number.
IQR, interquartile range; NS, not significant.
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changes in the ACR and the achieved systolic BP in all
patients from both groups (r¼0.029, P¼ 0.793), mono-
therapy group (r¼ 0.045, P¼ 0.772), and the combination
group (r¼0.123, P¼ 0.445).
We next separated the 87 patients into hypertensive
(n¼ 37) and normotensive (n¼ 43) subgroups (data of
hypertensive subgroup not shown). Based on a subgroup
analysis of the normotensive groups, there was no significant
difference in the reduction of ACR between the monotherapy
and combined therapy from baseline to 1 year (P¼ 0.097)
(Figure 3). Although a significant reduction was observed in
the systolic and diastolic BP in both groups from baseline to
1 year (systolic BP, Po0.0067; diastolic BP, Po0.0001), there
was no significant difference in the reduction of BP between
the monotherapy and combined therapy groups (systolic BP,
P¼ 0.351; diastolic BP, P¼ 0.631) (Table 3).
Adverse effects
In addition, no cardiovascular events and no edema were
seen in either group. Furthermore, no significant differences
of adverse events were noted between the groups (Table 4).
There were no significant changes in the serum creatinine,
potassium, or glycosylated hemoglobin levels in either group
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Figure 2 | Changes in the urinary ACR for the whole group. Results
are expressed as the mean7s.e. After 1 year, the decrease in the ACR
was greater with combined therapy (VþC) than with monotherapy
(V) (reduction rate 44711% versus 977%; P¼ 0.017 by analysis
of covariance).
Table 2 | Progression and regression of albuminuria
Valsartan Valsartan+cilnidipine P-value
Total 41 46
Normoalbuminuria 12 17
Microalbuminuria 29 29
From normoalbuminuria
To microalbuminuria 3 (25.0%) 1 (5.9%) 0.31
From microalbuminuria
To overt proteinuria 1 (3.4%) 0 ( 0.0%) 40.99
From microalbuminuria
To normoalbuminuria 5 (17.2%) 11 (37.9%) 0.26
Table 3 | Systolic and diastolic BP at baseline and during follow-up
Whole population Normotensive subgroup
SBP DBP SBP DBP
V V+C V V+C V V+C V V+C
Baseline 140714 134711 1179 76710 12776 12878 7379 74710
Month 1 135718 125711 7479 74710 125711 12078 71710 73710
Month 2 128716 127716 74710 7179 122711 123711 72712 7179
Month 3 130718 126713 72711 7277 123712 125713 69711 7278
Month 4 132716 125715 74711 7379 127714 121711 72711 7179
Month 5 132715 126713 74711 7478 125713 124714 75712 7578
Month 6 133719 129712 75710 7579 128717 126710 7479 7477
Month 7 134713 131715 74710 7477 131710 126711 76711 7577
Month 8 134716 132712 77710 7676 126712 128710 77712 7577
Month 9 137714 128714 7878 7378 134711 123710 7978 7177
Month 10 133717 131711 7579 7576 127713 12879 76711 7477
Month 11 136716 131712 7879 7678 136712 126711 79710 7577
Month 12 132714 131711 79710 7476 12878 12579 7978 7377
Results are expressed as the mean7s.d.
BP, blood pressure; C, cilnidipine; DBP, diastolic blood pressure; NS, not significant; SBP, systolic blood pressure; V, valsartan.
200
150
100
50
0
0 3 6 9 12
Months
AC
R 
ch
an
ge
 (%
)
ACR (V)
ACR (V+C)
Figure 3 | Changes of the urinary ACR in the normotensive group.
Results are expressed as the mean7s.e. Although the normotensive
group had a similar ACR curve to that of the whole group, there was
no significant difference in the reduction of ACR between the
monotherapy and combined therapy group from baseline to 1 year.
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(Table 5). The final dose of valsartan was not significantly
different between the two groups (63733 mg for mono-
therapy and 65726 mg for combined therapy). The final
dose of cilnidipine was 773 mg.
DISCUSSION
In the present trial, combined therapy with valsartan plus
cilnidipine was significantly more effective than valsartan
monotherapy for reducing albuminuria in type II diabetics.
This analysis was performed using the achieved BP values
according to recent recommendations.10,11 In addition, these
findings did not change when using the change in BP instead
of the achieved BP (data not shown).
At present, it is not clear how great a decrease of
albuminuria is necessary to obtain a sufficient renoprotective
effect. In our study, combined therapy with an ARB plus
cilnidipine reduced albuminuria by 44% and this treatment
was thus found to be superior to ARB monotherapy.
Accordingly, to achieve an adequate renoprotective effect, a
combination of drugs that can achieve a reduction of
albuminuria should probably be selected. In addition, a
regression of microalbuminuria to normoalbuminuria was
more common in the combined therapy group. On the other
hand, a progression from normoalbuminuria to microalbu-
minuria was more common in the monotherapy group and
one patient also progressed to overt proteinuria in this group.
As a result, the combined therapy thus prevented the
progression of albuminuria as well as the normalization of
microalbuminuria more frequently than the monotherapy
group.
In another Japanese trial, no significant difference was
seen in microalbuminuria levels between those patients
treated with an ACE inhibitor and nifedipine therapy
(blocking L-type calcium channels).12 In addition, combina-
tion therapy with an ACE inhibitor and amlodipine (an
L-type blocker) more effectively reduced microalbuminuria
than ACE inhibitor monotherapy. However, this result largely
depended on the BP-lowering effect.13 In these previous
Japanese studies, both drugs (nifedipine and amlodipine)
were L-type dihydropyridine CCBs. In our study, the
combination of an ARB with an L-/N-type dihydropyridine
CCB demonstrated its effectiveness for reducing albuminuria
and moreover there was no statistical correlation between the
changes in the ACR and the achieved systolic BP.
Although no significant difference was seen in the change
of the BP between the two groups, better BP control may be
one of the factors that make combined therapy more
effective. According to a subgroup analysis of the Modifica-
tion of Diet in Renal Disease trial, the BP reduction was
shown to be more important than the type of antihyperten-
sive drugs used when trying to achieve a renoprotective
effect.14 However, our outcome was observed after correcting
for BP in the analysis of covariance model and there was a no
statistical correlation between the changes in the ACR and the
achieved systolic BP. From these results, the reduction of
albuminuria with the combined therapy might not be due to
only a BP-lowering effect. Therefore, we also performed an
analysis of our normotensive and hypertensive subgroups.
The normotensive group had a similar ACR curve to that of
the whole group and the combined group showed a better
efficacy than the monotherapy group, although the total
number of subjects was not large enough to confirm this
statistically. From this result, the use of cilnidipine with ARB
might therefore demonstrate a renoprotective effect of ARB
in the normotensive group.
In both groups, no critical cardiovascular events were
observed. The serum creatinine and potassium levels
remained unchanged between the baseline and 6 months,
and neither group experienced a negative influence on the
renal function. After starting this trial, 12 patients withdrew
from each group, showing no significant difference. In
addition, no difference was seen in the side effects and
compliance between the combined therapy and monotherapy
groups.
There were several limitations to this trial. First, the ACR
was calculated instead of measuring the urinary albumin
excretion, because 24-h urine collection was difficult to
perform for outpatients and the ACR shows a positive
correlation with albumin excretion.15–17 In addition, regard-
ing the screening, the ratio of the patients with overt
proteinuria, 743/861, was higher than in other Japanese
populations. As there are 5 of 11 medical doctors engaged in
the nephrology section at our hospital, the patients with renal
Table 4 | Adverse events
Valsartan Valsartan+cilnidipine
Death 0 0
Non-fatal cardiovascular events 0 0
Other non-fatal events
Hypotension 6 7
Skin reaction 2 2
Discontinuation 1 0
Moved away 3 2
Protocol violation 0 1
Table 5 | Changes of clinical data
Variable Valsartan Valsartan+cilnidipine P-value
Cr (mg/dl)
Baseline 0.870.3 0.770.2 NS
6 Months 0.870.3 0.770.2 NS
K (mEq/l)
Baseline 4.370.3 4.470.4 NS
6 Months 4.470.5 4.470.5 NS
HbA1c (%)
Baseline 7.671.4 7.771.6 NS
6 Months 7.371.2 7.671.3 NS
12 Months 7.771.6 7.571.5 NS
Results are expressed as the mean7s.d.
Cr, serum creatinine; HbA1c, glycosylated hemoglobin; K, serum potassium; NS, not
significant.
154 Kidney International
o r i g i n a l a r t i c l e K Katayama et al.: Cilnidipine in diabetes
diseases referred from local practitioners might be higher
than in other general hospitals. Moreover, any patients whose
urinalysis showed proteinuria at least once within the past 1
year were excluded at screening. As a result, the degree of
overt proteinuria might have been overestimated.
Second, this was a single-center, open-label study, so a
large-scale, multicenter, double-blind clinical trial will be
needed in the future. In addition, we did not include a group
given cilnidipine alone because the Owase General Hospital
Ethics Committee recommended ARB therapy as the first
choice for diabetic nephropathy. However, our results
demonstrated the effect of reducing albuminuria with
cilnidipine in an additive manner by administering ARB.
Third, the withdrawal of CCBs might not have been
sufficiently long. Among the CCBs used in this study,
amlodipine had the longest half-time. However, several
reports have reported the antihypertensive effects of amlo-
dipine to disappear clinically 2 weeks after its withdrawal.18,19
Fourth, the control of diabetes was not satisfactory in
either group, and this might have caused a modification
of the renal function. However, it is very difficult to
achieve optimal glycemic control, even in academic medical
centers.20
At present, we agree that a better control of BP is needed
and ARB is the most effective drug to suppress the
progression of nephropathy.21 However, when ARBs cannot
improve BP fully, CCB can be the most effective additive
drug. In the Reduction of Endpoints in NIDDM with
Angiotensin II Antagonist Losartan (RENAAL) trial, almost
80% of the patients were administered CCB to achieve a
reduction in their BP in the ARB group and the placebo
group.3 In this regard, it is reasonable to use an L-/N-type
CCB with ARB.
In conclusion, the combination therapy using ARB plus
cilnidipine was found to more effectively reduce albuminuria
in type II diabetics than monotherapy with ARB. In the
course of diabetic albuminuria, combination therapy using
ARB and L-/N-type CCB may therefore be recommended as
the therapy of choice.
MATERIALS AND METHODS
Participants
This study was an open-label, randomized controlled trial
conducted at Owase General Hospital from April 2002 to October
2003. The total population of the region was 55 309 in 2002. The
study was approved by the Owase General Hospital Ethics
Committee and undertaken in accordance with the Declaration of
Helsinki Principles. Written informed consent was obtained from all
patients. Type 2 diabetic patients were enrolled if their median
urinary ACR obtained from three consecutive measurements was in
the range of 10–300 mg/g during an 8-week period before entry. The
ACR was measured using the immunoturbidimetry method.
Normoalbuminuria, microalbuminuria, and overt proteinuria were
defined as an ACR of 10–30, 30–300, and over 300 mg/g, respectively.
Other inclusion criteria were a baseline serum creatinine
concentration of below 2.0 mg/dl and a baseline BP of below 180/
105 mm Hg. The exclusion criteria were an age younger than 30
years; type I diabetes; the use of ACE inhibitors, ARBs, and CCBs in
the 4 weeks before randomization; treatment with corticosteroids or
immunosuppressants; myocardial infarction or a cerebrovascular
accident within the preceding 6 months; severe peripheral vascular
disease; severe congestive heart failure (New York Heart Association
classes III–IV); chronic hepatic disease; chronic pulmonary disease;
cancer; pregnancy; and breast-feeding. Patients could be withdrawn
from the trial because of the occurrence of intolerable side effects,
the fulfillment of the exclusion criteria, non-compliance, or protocol
violations. Patients were not excluded if they failed to reach the
target BP. The enrolled patients were randomly allocated into a
valsartan monotherapy group or a combined therapy with valsartan
plus cilnidipine group by an independent controller using the
envelope method.
Interventions
The patients in the monotherapy group received valsartan orally
once a day in the morning starting from 40 mg and titrated up to
80 mg to achieve a target BP under 130/85 mm Hg. In the combined
therapy group, the patients were treated with oral valsartan
(40–80 mg daily) and cilnidipine (5–10 mg daily) to achieve a target
BP under 130/85 mm Hg. Both drugs were given once daily in the
morning. When valsartan monotherapy failed to achieve the target
BP, amlodipine was added, and a third drug (other than an ACE
inhibitor) was used if necessary. If combined therapy failed to
achieve the target BP, then the cilnidipine was titrated up to 20 mg
and then another antihypertensive drug (except an ACE inhibitor)
was added. The compliance of the patients was checked once a
month at the outpatient clinic.
At the time of screening, CCBs were withdrawn from 27 patients
(amlodipine 6, benidipine 4, efonidipine 1, nicardipine 2, nifedipine
7, nilvadipine 2, nisoldipine 1, and diltiazem 4) 4 weeks before study
entry and were replaced with diuretics, a- or b-blockers, or centrally
acting agents to maintain BP control. Hypertension was defined as a
BP over 140/90 mm Hg and/or the use of antihypertensive therapy at
baseline. The BP was measured at monthly intervals using a mercury
sphygmomanometer, with the patient in the sitting position after at
least 5 min of rest. The target BP was defined as 130/85 mm Hg.22
Patients were followed up every month during the trial and the
dietary intake of sodium chloride was restricted to 7 g/day.
Outcome measures
The primary end point was the percent change in the urinary ACR
from baseline to 1 year. The secondary end points were a
progression/regression of albuminuria, BP, renal function, and
safety. BP was measured monthly and urinary ACR was monitored
every 3 months. The glycosylated hemoglobin level was measured at
baseline as well as after 6 and 12 months, while the serum creatinine
and potassium levels were measured at baseline and after 6 months.
Statistical analysis
The data were expressed as the mean and s.d. for continuous
normally distributed variables, or as the geometric mean and
interquartile ratio for ordinal or non-normally distributed variables.
Comparisons of the mean values were performed with the unpaired
t-test or the paired t-test. As the ACR data showed a skewed
distribution, raw values were log-transformed for calculation and
the percent change from baseline was calculated. For the
simultaneous assessment of the effect of treatment on the changes
from baseline in ACR, adjusted for confounding factors (i.e. age,
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sex), an analysis of covariance models on the log-transformed ACR
was used. To further investigate whether the baseline ACR, BP status
(normotension or hypertension), and the achieved systolic BP
explain the differences in ACR between treatments, the baseline
ACR, BP status (normotension or hypertension), and the achieved
systolic BP were also included as covariates. Fisher’s exact test was
used to compare the proportion of patients between the mono-
therapy and combined therapy groups. The course of BP was
evaluated by repeated-measure analysis of variance. A correlation
analysis was performed using Pearson’s correlation test. All patients
in whom the ACR data could be evaluated more than two times
during the follow-up occasions were analyzed using an intention-to-
treat analysis. Differences were considered statistically significant at
Po0.05 and the Statview version 5.0 software package (SAS
statistical software) was used for all calculations.
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